On May 16, a groundbreaking procedure took place at Terrebonne General Health System (Terrebonne General), marking a significant milestone in the treatment of chronic limb-threatening ischemia (CLI) in the Gulf South. Terrebonne General and the Cardiovascular Institute of the South (CIS) became the first institutions in this region, and one of only five in the entire United States, to employ the newly FDA-approved Esprit™ BTK (Below the Knee) Everolimus Eluting Resorbable Scaffold System. This innovative dissolvable stent, designed to treat artery disease in the lower legs, represents a pioneering step forward in vascular intervention, as per this article from The Houma Times.

The landmark procedure was conducted by CIS interventional cardiologist Dr. Pradeep Nair in the cath lab at Terrebonne General. The Esprit™ BTK System, developed by Abbott, was implanted through a minimally invasive process. This system works by keeping the arteries open while administering the drug Everolimus, which promotes vessel healing and helps prevent future blockages. Remarkably, the scaffold provides structural support for about three years before it gradually dissolves, much like the material used in sutures or stitches.

Before the introduction of the Esprit™ BTK System, the treatment options for blockages below the knee were limited and less effective. The traditional approach involved balloon angioplasty, where a small balloon is inserted via a catheter to open the vessel and restore blood flow. Unfortunately, this method often yielded inconsistent results both in the short term and long term, with a significant risk of re-blockage over time. The advent of the Esprit™ BTK System, therefore, represents a significant advancement in providing lasting relief for patients suffering from chronic limb-threatening ischemia.

Dr. Pradeep Nair, who played a pivotal role in the research trial that led to the device’s FDA approval, elaborated on the significance of this development. He pointed out that patients with chronic limb-threatening ischemia are perpetually at risk of losing their legs, with many experiencing blockages in the tibial arteries below the knee. Dr. Nair emphasized the revolutionary nature of the new system, highlighting its dual benefits of drug elution and vessel scaffolding, which not only keep the vessels open longer but also completely resorb into the body over time. He regarded this technology as transformative for patients suffering from chronic limb ischemia.

Phyllis Peoples, President and CEO of Terrebonne General, expressed immense pride and excitement about offering this cutting-edge technology to their patients. She underscored the long-standing partnership of 41 years with CIS, which has been instrumental in bringing advanced cardiology services to the community. Peoples reaffirmed the health system’s commitment to high-quality care and its continuous efforts to adopt the most advanced procedures to better serve their patients and community.

Chronic limb-threatening ischemia is a severe stage of peripheral artery disease (PAD), which affects the blood vessels in the legs. This condition can lead to symptoms such as painful cramping during physical activity, persistent sores, numbness, coldness, discoloration, or a weak pulse in the foot or leg. These symptoms indicate a critical need for medical intervention to prevent severe complications, including limb loss. Individuals experiencing these symptoms are advised to seek prompt consultation with their cardiologist.

The introduction of the Esprit™ BTK System at Terrebonne General marks a transformative advancement in the treatment of chronic limb-threatening ischemia. By utilizing this innovative dissolvable stent, patients in the Gulf South now have access to cutting-edge technology that significantly improves long-term outcomes. Terrebonne General and CIS continue to lead the way in providing high-quality, advanced care, underscoring their commitment to enhancing patient health and well-being in the community.

For more Louisiana-related articles, click here.